GITR+ regulatory T cells in the treatment of autoimmune diseases

Autoimmunity Reviews

Volumn 14, Issue 2, 2015, Pages 117-126

  Petrillo, Maria Grazia ^a   Ronchetti, Simona ^a   Ricci, Erika ^a   Alunno, Alessia ^a   Gerli, Roberto ^a   Nocentini, Giuseppe ^a   Riccardi, Carlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MURINE MODEL; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CYTOLOGY; DISEASE COURSE; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; DISEASE PROGRESSION; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; T-LYMPHOCYTES, REGULATORY;

EID: 84922546786     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.011     Document Type: Review

References (127)

1. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
2. Geiger T.L., Tauro S. Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function. Hum Immunol 2012, 73:232-239.
3. +CD25-lymphocytes is thymus and proliferation independent. Cancer Res 2006, 66:4488-4495.
4. Wainwright D.A., Sengupta S., Han Y., Lesniak M.S. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011, 13:1308-1323.
5. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
6. Gerli R., Nocentini G., Alunno A., Bocci E.B., Bianchini R., Bistoni O., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009, 8:426-430.
7. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-242.
8. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
9. + T regulatory cells. J Immunol 2010, 184:3433-3441.
10. + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10:744-755.
11. Miyara M., Ito Y., Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol 2014, 10:543-551.
12. high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006, 45:1210-1217.
13. Lina C., Conghua W., Nan L., Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:596-605.
14. Kim J.R., Chae J.N., Kim S.H., Ha J.S. Subpopulations of regulatory T cells in rheumatoid arthritis, systemic lupus erythematosus, and Behcet's disease. J Korean Med Sci 2012, 27:1009-1013.
15. Szodoray P., Nakken B., Barath S., Csipo I., Nagy G., El-Hage F., et al. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. Hum Immunol 2013, 74:1510-1518.
16. + T cells contributes to enhanced disease activity in patients with rheumatoid arthritis through IL-10 regulation. Eur Rev Med Pharmacol Sci 2014, 18:78-85.
17. Nie H., Zheng Y., Li R., Guo T.B., He D., Fang L., et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013, 19:322-328.
18. + T cells in systemic lupus erythematosus patients. Arthritis Res Ther 2014, 16:444.
19. Alunno A., Bartoloni E., Bistoni O., Nocentini G., Ronchetti S., Caterbi S., et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012, 2012:823085.
20. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
21. Thompson J.A., Perry D., Brusko T.M. Autologous regulatory T cells for the treatment of type 1 diabetes. Curr Diab Rep 2012, 12:623-632.
22. + T-cell compartment in the 1st year of human type 1 diabetes. Diabetes 2011, 60:2125-2133.
23. + CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One 2013, 8:e83811.
24. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008, 4:384-398.
25. Carbone F., De Rosa V., Carrieri P.B., Montella S., Bruzzese D., Porcellini A., et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat Med 2014, 20:69-74.
26. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
27. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:18538-18543.
28. Schaer D.A., Murphy J.T., Wolchok J.D. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012, 24:217-224.
29. Lu L., Xu X., Zhang B., Zhang R., Ji H., Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 2014, 12:36.
30. Giraldo N.A., Becht E., Remark R., Damotte D., Sautes-Fridman C., Fridman W.H. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014, 27C:8-15.
31. Yi S., Ji M., Wu J., Ma X., Phillips P., Hawthorne W.J., et al. Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. Diabetes 2012, 61:1180-1191.
32. Cuzzocrea S., Ayroldi E., Di Paola R., Agostini M., Mazzon E., Bruscoli S., et al. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J 2005, 19:1253-1265.
33. Santucci L., Agostini M., Bruscoli S., Mencarelli A., Ronchetti S., Ayroldi E., et al. GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut 2007, 56:52-60.
34. Davidson T.S., Shevach E.M. Polyclonal Treg cells modulate T effector cell trafficking. Eur J Immunol 2011, 41:2862-2870.
35. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
36. Cannarile L., Fallarino F., Agostini M., Cuzzocrea S., Mazzon E., Vacca C., et al. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. Blood 2006, 107:1039-1047.
37. Bereshchenko O., Coppo M., Bruscoli S., Biagioli M., Cimino M., Frammartino T., et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. Cell Rep 2014, 7:464-475.
38. + regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 2011, 32:158-166.
39. Jethwa H., Adami A.A., Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?. Clin Immunol 2014, 150:51-63.
40. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
41. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
42. Edinger M., Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011, 23:679-684.
43. - T regulatory cells. Clin Immunol 2009, 133:22-26.
44. Bacchetta R., Lucarelli B., Sartirana C., Gregori S., Lupo Stanghellini M.T., Miqueu P., et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. Front Immunol 2014, 5:16.
45. Gregori S., Goudy K.S., Roncarolo M.G. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012, 3:30.
46. Himmel M.E., Yao Y., Orban P.C., Steiner T.S., Levings M.K. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology 2012, 136:115-122.
47. Lio C.W., Hsieh C.S. A two-step process for thymic regulatory T cell development. Immunity 2008, 28:100-111.
48. Burchill M.A., Yang J., Vang K.B., Moon J.J., Chu H.H., Lio C.W., et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 2008, 28:112-121.
49. Mahmud S.A., Manlove L.S., Schmitz H.M., Xing Y., Wang Y., Owen D.L., et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol 2014, 15(5):473-481.
50. Ronchetti S., Nocentini G., Riccardi C., Pandolfi P.P. Role of GITR in activation response of T lymphocytes. Blood 2002, 100:350-352.
51. + T cells. J Immunol 2004, 173:5008-5020.
52. Nocentini G., Ronchetti S., Cuzzocrea S., Riccardi C. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 2007, 37:1165-1169.
53. Ronchetti S., Zollo O., Bruscoli S., Agostini M., Bianchini R., Nocentini G., et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004, 34:613-622.
54. + T cells in vivo. J Immunol 2009, 182:7490-7500.
55. + regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 2012, 242:39-46.
56. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007, 7:585-598.
57. Carrier Y., Whitters M.J., Miyashiro J.S., LaBranche T.P., Ramon H.E., Benoit S.E., et al. Enhanced GITR/GITRL interactions augment IL-27 expression and induce IL-10-producing Tr-1 like cells. Eur J Immunol 2012, 42:1393-1404.
58. Liao G., O'Keeffe M.S., Wang G., van Driel B., de Waal Malefyt R., Reinecker H.C., et al. Glucocorticoid-induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4(+) T cells. Front Immunol 2014, 5:35.
59. Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012, 7:e35981.
60. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
61. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
62. Zelenika D., Adams E., Humm S., Graca L., Thompson S., Cobbold S.P., et al. Regulatory T cells overexpress a subset of Th2 gene transcripts. J Immunol 2002, 168:1069-1079.
63. Nocentini G., Riccardi C. GITR: a modulator of immune response and inflammation. Adv Exp Med Biol 2009, 647:156-173.
64. + T regulatory cells. Nat Immunol 2003, 4:337-342.
65. +regulatory T cells. J Immunol 2003, 171:708-716.
66. - regulatory T cells. J Immunol 2006, 176:4748-4756.
67. Sacchetti C., Rapini N., Magrini A., Cirelli E., Bellucci S., Mattei M., et al. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem 2013, 24:852-858.
68. + Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003, 74:296-308.
69. bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172:6435-6443.
70. bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004, 173:3119-3130.
71. Heikkinen J., Mottonen M., Alanen A., Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol 2004, 136:373-378.
72. Benevides L., Cardoso C.R., Tiezzi D.G., Marana H.R., Andrade J.M., Silva J.S. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 2013, 43:1518-1528.
73. + regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013, 57:183-194.
74. Bacchetta R., Gambineri E., Roncarolo M.G. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007, 120:227-235. [quiz 36-7].
75. Veldman C., Pahl A., Beissert S., Hansen W., Buer J., Dieckmann D., et al. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. J Immunol 2006, 176:3215-3222.
76. + T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1T regulatory cells. J Exp Med 2002, 196:1335-1346.
77. Bianchini R., Bistoni O., Alunno A., Petrillo M.G., Ronchetti S., Sportoletti P., et al. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol 2011, 41:2269-2278.
78. Battaglia M., Gregori S., Bacchetta R., Roncarolo M.G. Tr1 cells: from discovery to their clinical application. Semin Immunol 2006, 18:120-127.
79. Gagliani N., Magnani C.F., Huber S., Gianolini M.E., Pala M., Licona-Limon P., et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013, 19:739-746.
80. Luczynski W., Wawrusiewicz-Kurylonek N., Stasiak-Barmuta A., Urban R., Ilendo E., Urban M., et al. Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta Biochim Pol 2009, 56:361-370.
81. + T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients. Int Immunol 2013, 25:563-574.
82. Padovani C.T., Bonin C.M., Tozetti I.A., Ferreira A.M., Fernandes C.E., Costa I.P. Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection. Rev Soc Bras Med Trop 2013, 46:288-292.
83. von Rahden B.H., Kircher S., Kafka M., Stuermer L., Reiber C., Gattenlohner S., et al. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa. Cancer Biomark 2010, 7:285-294.
84. Krausz L.T., Fischer-Fodor E., Major Z.Z., Fetica B. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer patients as compared to tumor-negative lymph nodes. Int J Immunopathol Pharmacol 2012, 25:59-66.
85. Goode E.L., DeRycke M., Kalli K.R., Oberg A.L., Cunningham J.M., Maurer M.J., et al. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One 2013, 8:e53903.
86. Tomizawa R., Watanabe M., Inoue N., Takemura K., Hidaka Y., Akamizu T., et al. Association of functional GITR gene polymorphisms related to expression of glucocorticoid-induced tumour necrosis factor-receptor (GITR) molecules with prognosis of autoimmune thyroid disease. Clin Exp Immunol 2011, 165:141-147.
87. Rajaraman P., Brenner A.V., Neta G., Pfeiffer R., Wang S.S., Yeager M., et al. Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev 2010, 19:1356-1361.
88. + T cell subset in primary Sjogren's syndrome. Rheumatology (Oxford) 2013, 52:1387-1396.
89. + Tregs in a Hodgkin's lymphoma patient presenting with myasthenia-like symptoms. Ideggyogy Sz 2013, 66:343-348.
90. Nocentini G., Ronchetti S., Petrillo M.G., Riccardi C. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol 2012, 165:2089-2099.
91. Ponte J.F., Ponath P., Gulati R., Slavonic M., Paglia M., O'Shea A., et al. Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. Immunology 2010, 130:231-242.
92. + regulatory T cells mediated by GITR molecules. Immunol Lett 2008, 121:97-104.
93. + regulatory T cells. Int Immunol 2010, 22:259-270.
94. Schaer D.A., Budhu S., Liu C., Bryson C., Malandro N., Cohen A., et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013, 1.
95. Wyzgol A., Muller N., Fick A., Munkel S., Grigoleit G.U., Pfizenmaier K., et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009, 183:1851-1861.
96. Cui D., Wang S., Chen Y., Tong J., Ma J., Tang L., et al. An isoleucine-zipper motif enhances costimulation of human soluble trimeric GITR ligand. Cell Mol Immunol 2010, 7:316-322.
97. Stone G.W., Barzee S., Snarsky V., Spina C.A., Lifson J.D., Pillai V.K., et al. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 2006, 13:1223-1230.
98. Spinicelli S., Nocentini G., Ronchetti S., Krausz L.T., Bianchini R., Riccardi C. GITR interacts with the pro-apoptotic protein Siva and induces apoptosis. Cell Death Differ 2002, 9:1382-1384.
99. Tone M., Tone Y., Adams E., Yates S.F., Frewin M.R., Cobbold S.P., et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003, 100:15059-15064.
100. Tabares P., Berr S., Romer P.S., Chuvpilo S., Matskevich A.A., Tyrsin D., et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 2014, 44:1225-1236.
101. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013, 210:1685-1693.
102. De Groot A.S., Terry F., Cousens L., Martin W. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Rev Clin Pharmacol 2013, 6:651-662.
103. Hartemann A., Bensimon G., Payan C.A., Jacqueminet S., Bourron O., Nicolas N., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, 1:295-305.
104. + regulatory T cell development. J Immunol 2008, 181:3285-3290.
105. Zhou X., Bailey-Bucktrout S., Jeker L.T., Bluestone J.A. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009, 21:281-285.
106. + regulatory T cells. J Exp Med 2005, 202:885-891.
107. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009, 10:1000-1007.
108. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007, 178:6725-6729.
109. Joetham A., Ohnishi H., Okamoto M., Takeda K., Schedel M., Domenico J., et al. Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation. J Biol Chem 2012, 287:17100-17108.
110. Joetham A., Schedel M., Takeda K., Jia Y., Ashino S., Dakhama A., et al. JNK2 regulates the functional plasticity of naturally occurring T regulatory cells and the enhancement of lung allergic responses. J Immunol 2014, 193:2238-2247.
111. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006, 203:359-370.
112. - T cells by regulatory T cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:1112-1119.
113. Alonso N., Martinez-Arconada M.J., Granada M.L., Soldevila B., Canton A., Mate J.L., et al. Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis. Endocrine 2009, 35:420-428.
114. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010, 185:3814-3818.
115. Ryba M., Rybarczyk-Kapturska K., Zorena K., Mysliwiec M., Mysliwska J. Lower frequency of CD62L(high) and higher frequency of TNFR2(+) Tregs are associated with inflammatory conditions in type 1 diabetic patients. Mediators Inflamm 2011, 2011:645643.
116. Ryba-Stanislawowska M., Skrzypkowska M., Mysliwiec M., Mysliwska J. Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum Immunol 2013, 74:701-707.
117. Jamshidian A., Shaygannejad V., Pourazar A., Zarkesh-Esfahani S.H., Gharagozloo M. Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. J Neuroimmunol 2013, 262:106-112.
118. Kouchaki E., Salehi M., Reza Sharif M., Nikoueinejad H., Akbari H. Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis. Iran J Basic Med Sci 2014, 17:250-255.
119. + regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 2011, 186:4734-4743.
120. Glick A.B., Wodzinski A., Fu P., Levine A.D., Wald D.N. Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid 2013, 23:871-878.
121. + T cell levels in children with autoimmune thyroid diseases. Autoimmunity 2013, 46:222-230.
122. +CD25 high T cells in naive Crohn's disease. Dig Dis Sci 2009, 54:2084-2093.
123. +, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 2009, 156:320-327.
124. High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, and following colectomy. Cytokine 2011, 56:466-470.
125. + regulatory T cells in inflammatory bowel disease. J Dig Dis 2011, 12:286-294.
126. Reikvam D.H., Perminow G., Lyckander L.G., Gran J.M., Brandtzaeg P., Vatn M., et al. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients. Scand J Gastroenterol 2011, 46:550-560.
127. Guidi L., Felice C., Procoli A., Bonanno G., Martinelli E., Marzo M., et al. FOXP3(+) T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFalpha agents. Biomed Res Int 2013, 2013:286368.